Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®
MONTREAL, Jan. 11, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, today announced it has entered into an exclusive License Agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) (“Puma“) granting Knight the exclusive right to commercialize NERLYNX® (neratinib) […]
Knight Therapeutics Announces Canadian Regulatory Approval for ILUVIEN®
MONTREAL, Nov. 26, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved ILUVIEN® for the treatment of diabetic macular edema (DME). ILUVIEN is a fluocinolone acetonide sustained release non-biodegradable intravitreal implant used to treat DME in patients who have been previously treated with a […]
Knight Therapeutics Reports Third Quarter 2018 Results
MONTREAL, Nov. 08, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2018. Q3 2018 Highlights Financials Revenues were $3,220, an increase of $1,360 or 73% over prior period. Net income was $12,930, an increase of $9,337 or 260% over prior […]
Notice of Knight Therapeutics' Third Quarter 2018 Results Conference Call
MONTREAL, Nov. 01, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2018 financial results on Thursday, November 8th, 2018 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
Knight Therapeutics Announces the Canadian launch of PROBUPHINE™ for Opioid Use Disorder
MONTREAL, Oct. 29, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today the commercial availability of PROBUPHINE™ (buprenorphine hydrochloride subdermal implant), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support1. Knight has […]
Knight to Present at the Cantor Fitzgerald Global Healthcare Conference in New York City
MONTREAL, Sept. 25, 2018 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 12:15 pm ET, at the Intercontinental New York Barclay Hotel in New York […]
Knight Therapeutics and Jaguar Health Announce Strategic Partnership
Knight receives license to Mytesi® and related products in Canada and Israel MONTREAL and SAN FRANCISCO, Sept. 24, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, and Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a […]
Knight to Participate at the Morgan Stanley Global Healthcare Conference in New York City
MONTREAL, Sept. 06, 2018 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, will participate in a fireside chat at the 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 3:30 pm ET at the Grand Hyatt in […]
Knight Disposes of a Toddler-Sized Amount of Pediapharm Inc.
MONTREAL, Aug. 31, 2018 — This press release is being disseminated by Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a specialty pharmaceutical company, as required by National Instrument 62-103 – The Early Warning System and Related Take Over Bid and Insider Reporting Issues regarding the disposition of securities of Pediapharm Inc. (“Pediapharm”). Since July 4, 2018, Knight […]
Knight Therapeutics Reports Second Quarter 2018 Results
MONTREAL, Aug. 09, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2018. Q2 2018 Highlights Financials Revenues were $2,238, a decrease of $242 or 10% versus prior period Net income was $4,019, an increase of $3,560 or 776% over […]
